COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00480441
Recruitment Status : Completed
First Posted : May 31, 2007
Results First Posted : July 29, 2019
Last Update Posted : July 29, 2019
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Marina Goldman, University of Pennsylvania

Brief Summary:

This treatment study is targeted specifically for those who want to stop using marijuana. We want to find out if patients who are dependent on marijuana and want to stop using are helped by a combination of the drug dronabinol and six sessions of individual therapy (BRENDA). Dronabinol is a pill form of the active ingredient in marijuana (THC). Currently, dronabinol is approved for the treatment of nausea in people receiving cancer chemotherapy and as an appetite stimulant in people with AIDS.

In some studies, dronabinol reduced the amount of psychological and physical discomfort experienced when people stopped using marijuana. One purpose of our study is to see if people who are on dronabinol have fewer problems with psychological and physical discomfort than those who are on a placebo.

In addition to treatment, this research trial will also be measuring the reactions of subjects to drug-related cues, and also to computer-presented tasks unrelated to drug use. We may examine whether the response to these cues/tasks either predicts treatment outcome, or is affected by your treatment. This information may also help us to understand the ways in which chronic drug use causes changes in our subjects' mental functioning and how those changes respond to treatment.

In addition to participation in the treatment research trial, some subjects may be asked to undergo a brain scan in an MRI. The purpose of the brain scan research project is to measure brain reactions with a non-invasive, non-radioactive imaging technique known as fMRI (functional magnetic resonance imaging) in marijuana subjects before and after treatment with the medication dronabinol or with an inactive substance (placebo).

Condition or disease Intervention/treatment Phase
Marijuana Dependence Drug: Dronabinol Behavioral: BRENDA therapy Drug: Placebo Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II Double-Blind Placebo-Controlled Trial of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal
Study Start Date : August 2006
Actual Primary Completion Date : June 2009
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana
Drug Information available for: Dronabinol

Arm Intervention/treatment
Active Comparator: 1
Dronabinol+ BRENDA therapy
Drug: Dronabinol
10mg capsules taken 4 times daily for 2 weeks and then tapered over 1 week
Other Name: Marinol

Behavioral: BRENDA therapy
weekly therapy sessions for 6 weeks

Placebo Comparator: 2
Placebo+BRENDA therapy
Behavioral: BRENDA therapy
weekly therapy sessions for 6 weeks

Drug: Placebo
4 capsules daily for 2 weeks followed by a 1 week taper

Primary Outcome Measures :
  1. Physiological Changes in Response to Cue-induced Craving. [ Time Frame: Baseline functional mri (fMRI), (prior to randomization) ]
    Functional MRI brain response to cannabis vs neutral cues. Higher T values represent increased blood flow in response to cues.

  2. Tolerability of Treatment [ Time Frame: baseline to two years ]
    Reports of side effects leading to discontinuation of treatment were examined in all participants.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males and females, 18-55 years old
  2. Meets DSM-IV criteria for Cannabis Dependence
  3. History of chronic cannabis use of moderate intensity defined by 10 or more years of use with an average frequency of 2 or more joints/day on 5 or more days/week
  4. Live within a commutable distance of the Treatment Research Center
  5. Understand and sign the informed consent
  6. Voluntarily seeking treatment for cannabis dependence

Exclusion Criteria:

  1. Current DSM-IV diagnosis of any psychoactive substance dependence other than marijuana, or nicotine dependence
  2. Concomitant treatment with sedative hypnotics, opioid analgesics or other known CNS depressants at a dose and frequency that is unacceptable to the principal investigator
  3. Mandated to treatment based upon a legal decision or as a condition of employment
  4. Current severe psychiatric symptoms, e.g. psychosis, dementia, acute suicidal or homicidal ideation, mania or depression requiring antidepressant therapy, or which could make it unsafe for the patient to participate in the opinion of the primary investigators
  5. History of significant, unstable heart disease, including myocardial infarction, unstable angina, cardiac failure, second or third degree heart block, uncontrolled hypertension, syncope
  6. Known hypersensitivity to cannabinoids or sesame oil
  7. Any serious medical illness, which may require hospitalization during the study (i.e. sickle cell anemia, rheumatoid arthritis)
  8. Has any disease of the gastrointestinal system, liver or kidneys which could result in altered metabolism or excretion of the study medication (history of major gastrointestinal tract surgery, gastrectomy, gastrotomy, bowel resection, etc.) or history of chronic gastrointestinal disorders (ulcerative colitis, regional enteritis, or gastrointestinal bleeding)
  9. Female subjects who are pregnant or lactating, or female subjects of child bearing potential who are not using acceptable methods of birth control. Acceptable methods of birth control include:

    Barrier (diaphragm or condom) with spermicide, Intrauterine device, Levonorgestrel implant, Medroxyprogesterone acetate contraceptive injection, Oral contraceptives.

  10. Clinical laboratory tests (CBC, blood chemistries, urinalysis) outside normal limits that are clinically unacceptable to the principal investigators. On EKG, 1st degree heart block, sinus tachycardia, left axis deviation, and nonspecific ST or T wave changes are allowed. Liver function tests (LFT's) <5 times ULN without symptoms of liver disease are acceptable after thorough medical review.

Additional Neuroimaging Exclusion Criteria:

Subjects who are selected for the clinical trial based on above inclusion and exclusion criteria will be screened further with the following exclusion criteria for possible participation in the fMRI imaging session:

  1. Participation in a clinical trial and receipt of investigational drug(s) other than this clinical trial during previous 60 days.
  2. History of serious head trauma or injury causing loss of consciousness that lasted more than 3 minutes.
  3. Presence of magnetically active prosthetics, plates, pins, broken needles, permanent retainer, bullets, etc. in subject's body (unless a radiologist confirms that its presence is unproblematic). An X-ray may be obtained to determine eligibility.
  4. Claustrophobia or other medical condition disabling subject from laying in the MRI for approximately 60 minutes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00480441

Layout table for location information
United States, Pennsylvania
Treatment Research Center at the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
National Institute on Drug Abuse (NIDA)
Layout table for investigator information
Principal Investigator: Charles O'Brien, M.D./Ph.D. Treatment Research Center at the University of Pennsylvania
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Marina Goldman, Principal Investigator, University of Pennsylvania Identifier: NCT00480441    
Other Study ID Numbers: 5P60DA005186-19 ( U.S. NIH Grant/Contract )
5P60DA005186-19 ( U.S. NIH Grant/Contract )
First Posted: May 31, 2007    Key Record Dates
Results First Posted: July 29, 2019
Last Update Posted: July 29, 2019
Last Verified: July 2019
Keywords provided by Marina Goldman, University of Pennsylvania:
Substance Withdrawal Syndrome
Clinical Trial
Behavioral Therapy
Neuropsychological Testing
Neurocognitive Testing
Behavioral Probes
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Cannabinoid Receptor Agonists
Cannabinoid Receptor Modulators
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists